Stockreport

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer  

Evogene Ltd. - Ordinary Shares  (EVGN) 
Last evogene ltd. - ordinary shares earnings: 2/28 07:00 am Check Earnings Report
US:NYSE Investor Relations: evogene.com/investor-relations
PDF REHOVOT, Israel and SHANGHAI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Evogene Ltd. (Nasdaq/TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing [Read more]